Review CJC-1295 benefits in human studies, including GH and IGF-1 findings, DAC identity, unpublished efficacy data and FDA safety limits.
CJC-1295 is often described online with a long list of benefits: more growth hormone, higher IGF-1, fat loss, muscle gain, better recovery, deeper sleep and “anti-aging.” The first two claims have direct human pharmacology data. Most of the rest do not.
Two small randomised, placebo-controlled studies in healthy adults showed that the long-acting DAC form produced sustained increases in circulating growth hormone (GH) and insulin-like growth factor 1 (IGF-1). A separate study found that GH secretion remained pulsatile one week after exposure. These results show that the molecule engaged the GH/IGF-1 axis. They did not test meaningful fat loss, muscle strength, injury recovery, sleep quality or longevity.[1–3]
A larger Phase 2 trial in people with HIV-associated visceral obesity was registered, but its efficacy results were not published. FDA’s 2024 review also documented a trial death, the investigator’s alternative explanation involving coronary disease, and the absence of enough information to establish causality. That history makes it especially important not to turn a biomarker response into a proven clinical benefit.[4,5]
The direct answer is: CJC-1295 with DAC has human evidence for prolonged GH and IGF-1 stimulation. Published human research has not established the broad body-composition, recovery, sleep or anti-aging benefits commonly claimed online.
CJC-1295 evidence at a glance
| Claim | What the evidence supports | What remains unproven |
|---|---|---|
| Raises GH | Small controlled trials found sustained, dose-related increases in mean GH[1] | Better recovery, strength, sleep or wellbeing |
| Raises IGF-1 | IGF-1 increased for days after exposure and accumulated with repeated exposure[1] | A favourable long-term clinical outcome |
| Preserves GH pulses | Twelve healthy men retained pulsatile secretion one week after exposure[2] | That the pattern is equivalent to normal physiology or risk-free |
| Changes other serum proteins | An exploratory analysis in 11 men found several protein-profile changes[3] | Clinical benefit from those changes |
| Reduces visceral fat | A Phase 2 HIV-visceral-obesity trial was registered[4] | Published efficacy results proving fat loss |
| Is “anti-aging” | No suitable trial established this | Longer life, slower ageing or disease prevention |
| Is safe | Short studies described tolerability in limited exposure | Long-term safety; FDA identifies limited data and serious safety concerns[5,6] |
First, define which CJC-1295
The name is not chemically precise enough for a procurement specification.
FDA’s 2024 review separated at least five related bulk drug substances: CJC-1295 free base, CJC-1295 acetate, CJC-1295 DAC free base, CJC-1295 DAC acetate and CJC-1295 DAC trifluoroacetate. It also found at least nine names used across nominations and literature.[5]
The published human pharmacology studies used the long-acting DAC form. DAC refers to the Drug Affinity Complex moiety added to the peptide. After administration, that reactive group forms a covalent bond with circulating albumin, extending exposure. This is the basis of the multi-day pharmacokinetic profile reported in the trials.[1,5]
Material marketed as “CJC-1295 without DAC” is not simply a shorter-lasting version with otherwise interchangeable evidence. It is a distinct molecular target. A separate CJC-1295 with DAC versus without DAC procurement guide is under editorial review; until that page is published, buyers should not transfer DAC trial results to a no-DAC label.
What the main controlled human study measured
Teichman and colleagues reported two randomised, double-blind, placebo-controlled ascending-dose studies in healthy adults aged 21–61. The studies lasted 28 and 49 days. Their main outcomes were pharmacokinetic measures and the blood concentrations of GH and IGF-1—not changes in body fat, muscle, exercise performance or symptoms.[1]
After a single exposure, mean GH concentrations increased approximately two- to ten-fold for six days or more. Mean IGF-1 increased about 1.5- to three-fold for nine to eleven days. The estimated half-life was 5.8–8.1 days. With repeated exposure, average IGF-1 remained above baseline for as long as 28 days.[1]
Those are substantial pharmacodynamic findings. They prove that CJC-1295 DAC can produce a durable endocrine signal in the studied setting. They do not tell us whether the signal produced a net health or performance benefit.
This distinction matters because GH and IGF-1 are biomarkers and biological mediators, not automatic outcome scores. “GH increased” cannot be silently rewritten as “muscle increased,” and “IGF-1 stayed elevated” is not evidence of faster injury recovery.
Did CJC-1295 flatten the normal GH pulse pattern?
A follow-up study examined 12 healthy men aged 20–40. Researchers sampled blood every 20 minutes overnight before and one week after exposure. They found that pulsatile GH secretion persisted. Mean GH, pulse area and trough concentrations increased, while the number of pulses did not materially change. Mean IGF-1 rose by 44% at one week.[2]
That finding is often summarised as “natural pulses are preserved.” A more accurate description is narrower: in 12 healthy men, during one overnight sampling period one week after CJC-1295 DAC, secretion remained pulsatile while baseline and pulse-related GH output increased.
It does not prove that prolonged stimulation is physiologically identical to an untreated state. It also does not turn pulse preservation into evidence for fat loss, sleep improvement or long-term safety.
The protein-profile study was exploratory
Another paper analysed stored serum from 11 healthy young men before and one week after exposure. The researchers used two-dimensional gel electrophoresis to explore proteins that might act as biomarkers of GH and IGF-1 action. They reported changes in several protein spots and discussed possible marker candidates.[3]
This was useful mechanistic work. It was not a trial of clinical benefits. Eleven participants, a before-and-after proteomic comparison and exploratory biomarker selection cannot establish improved immunity, metabolism, cognition or recovery.
Where are the fat-loss and body-composition results?
ClinicalTrials.gov lists a multicentre, randomised, placebo-controlled Phase 2 study of CJC-1295 in people with HIV-associated visceral obesity. The registry describes a 12-week study and lists 120 participants; FDA’s review discusses an anecdotal report of a related programme enrolling 192 participants. Publicly available published efficacy results were not identified in the sources reviewed here.[4,5]
The absence of published results is not proof that the treatment failed. It is also not permission to fill the gap with marketing claims. Without a report that provides the analysed population, endpoints, attrition, effect estimates and adverse events, readers cannot independently evaluate whether visceral fat or any other clinical outcome improved.
For an evidence article, the correct status is unresolved and unpublished, not “clinically proven fat loss.”
Safety cannot be inferred from short exposure
The 2006 pharmacology paper reported no serious adverse reactions in its short controlled studies. FDA’s later review gives the fuller context. Across three small published studies, 63 healthy adults received up to four exposures, and most received only one. Injection-site reactions were common; the FDA review also described headache, flushing, dizziness, nausea, abdominal symptoms, transient hypotension and increased heart rate in the available study reports.[1,5]
FDA’s current category page says compounded drugs containing CJC-1295 may present immunogenicity risks for certain routes and challenges involving peptide impurities and API characterisation. It notes serious adverse events including increased heart rate and systemic vasodilatory reaction, while emphasising that available clinical data are limited.[6]
The Phase 2 programme adds uncertainty. FDA reported that one participant experienced an acute myocardial infarction and died after an eleventh weekly exposure. The attending physician attributed the event most likely to previously asymptomatic coronary disease with plaque rupture, and the study was terminated. The public record does not allow a causal conclusion either way.[5]
It would therefore be inaccurate to write that CJC-1295 caused the death. It would be equally inaccurate to omit the event and declare long-term safety established.
Why a GH or IGF-1 change is not a complete benefit claim
An outcome claim needs an outcome-specific study. For example:
- fat loss requires validated body-composition measurements and an appropriate comparator;
- muscle gain requires defined mass and preferably function or strength outcomes;
- recovery requires a specified injury or workload and a prospective recovery endpoint;
- sleep improvement requires validated sleep measurements;
- anti-aging would require clearly defined age-related outcomes over an adequate duration.
The published CJC-1295 studies were designed mainly to ask whether hormone concentrations changed, for how long, and with what short-term tolerability. They should be read as pharmacology studies, not as proof of every downstream benefit that could be imagined from GH biology.
Translating the evidence into a B2B material specification
For a CJC-1295 research-material enquiry, the first task is identity. A useful RFQ should state:
- with DAC or without DAC;
- exact amino-acid sequence and terminal form;
- free base, acetate or TFA form;
- expected molecular formula and mass for that exact form;
- amount per vial and whether it is expressed as peptide, salt or another basis;
- identity method and acceptance criteria;
- chromatographic purity method and result;
- content or assay measurement, not purity alone;
- counter-ion, water, residual-solvent, impurity and aggregate scope where relevant;
- batch identifier linking the label, COA and tested sample;
- storage and shipment conditions for the quoted material.
FDA’s nomenclature review is a practical warning: a name can appear familiar while the structure, salt or DAC status remains unclear. HPLC area percentage alone cannot resolve that ambiguity. The peptide COA guide explains why identity, purity and content answer different questions.
Under MY PEPTIDE Wholesale Terms, each kit contains 10 vials of the same product and the standard MOQ is one kit per peptide. Full kits of different products may be combined in one order, but five vials of A and five of B do not form one kit. Quotations depend on the product, per-vial specification and quantity.
FAQ
What is the best-supported CJC-1295 benefit?
Published human studies most clearly support prolonged stimulation of GH and IGF-1 after CJC-1295 DAC exposure. That is a pharmacodynamic effect, not proof of a specific clinical benefit.[1]
Does CJC-1295 burn fat?
The sources reviewed here do not provide published controlled efficacy results establishing fat loss. A Phase 2 study in HIV-associated visceral obesity was registered, but a registration is not a published positive result.[4,5]
Does CJC-1295 build muscle?
The controlled human studies measured hormones and pharmacokinetics. They did not establish increased muscle mass, strength or athletic performance.
Is CJC-1295 with DAC the same as without DAC?
No. FDA treats them as distinct active moieties, and the published long-acting human evidence relates to the DAC form.[5]
Does CJC-1295 preserve natural GH pulses?
A study in 12 healthy men found that secretion remained pulsatile one week after exposure, with higher mean and trough GH. That small study does not prove complete physiological equivalence or long-term safety.[2]
Is CJC-1295 FDA-approved?
No FDA-approved drug containing CJC-1295 was identified in FDA’s 2024 review. FDA lists CJC-1295 among withdrawn bulk-substance nominations with potential significant safety risks for compounded products.[5,6]
Bottom line
CJC-1295 DAC has a real human evidence base, but it is narrower than most benefit lists suggest. Small controlled studies demonstrate prolonged GH and IGF-1 stimulation and show that pulsatile secretion can persist. They do not establish fat loss, muscle gain, recovery, better sleep or anti-aging outcomes.
The most useful lesson for a research buyer is equally narrow: specify the exact molecule before discussing evidence. DAC status, sequence, salt form, content basis and analytical identity are not minor label details; they determine whether the cited literature is even about the material being quoted.
For CJC-1295 forms, per-vial specifications, kit quantities and batch-document availability, contact service@wholesalepeptide.xyz.
References
- Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799–805. PubMed PMID 16352683 · DOI 10.1210/jc.2005-1536
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. Journal of Clinical Endocrinology & Metabolism. 2006;91(12):4792–4797. PubMed PMID 17018654 · DOI 10.1210/jc.2006-1702
- Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Hormone & IGF Research. 2009;19(6):471–477. PubMed PMID 19386527 · DOI 10.1016/j.ghir.2009.03.001
- US National Library of Medicine. A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity. NCT00267527. ClinicalTrials.gov record
- US Food and Drug Administration. Pharmacy Compounding Advisory Committee Meeting: CJC-1295-Related Bulk Drug Substances. December 4, 2024. FDA review PDF
- US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. Accessed September 18, 2026. FDA category page
This article is provided for supplier evaluation, research education, and business communication. It is not medical advice and does not provide dosage or treatment instructions.
Need supplier information for your business?
Discuss product availability, documentation, wholesale requirements, and shipping communication with our team.
